Literature DB >> 2948580

Differentiation of blast cells from a Down's syndrome patient with transient myeloproliferative disorder.

J Suda, M Eguchi, Y Akiyama, Y Iwama, T Furukawa, Y Sato, Y Miura, T Suda, M Saito.   

Abstract

A male neonate with Down's syndrome and congenital myeloproliferative disorder was studied. His blood picture showed the unique coexistence of leukocytosis with matured cells and a large number of blast cells. The in vitro proliferation and differentiation of blast cells into various lineages in the presence of phytohemagglutinin-stimulated leukocyte conditioned medium (PHA-LCM) was examined by using a liquid culture and a methylcellulose culture system. The differentiation of blast cells into myeloid cells was confirmed by specific cytochemical stainings, electron microscopy, and an immunologic study. No specific factors in the plasma of the patient promoted the proliferation or differentiation of blast cells. The cellular composition of colonies grown in methylcellulose culture from single blast cells was studied by a micromanipulation technique. High plating efficiency was observed. Of 136 cultures, 78 showed colony growth. Half of the blast cells were colony-forming cells that could proliferate and differentiate into basophils, neutrophils, eosinophils, macrophages, and erythrocytes in the presence of PHA-LCM. Using the blast cells with a high differentiation capacity to the basophil pathway, we studied the effect of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). Recombinant GM-CSF support neutrophils, eosinophils, and macrophages but not typical basophils. These findings of the cell differentiation of blast cells into various kinds of cells in vitro were in agreement with the finding of neutrophilia, eosinophilia, basophilia, and thrombocythemia in this patient.

Entities:  

Mesh:

Year:  1987        PMID: 2948580

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Isolation of a yeast artificial chromosome spanning the 8;21 translocation breakpoint t(8;21)(q22;q22.3) in acute myelogenous leukemia.

Authors:  J Gao; P Erickson; K Gardiner; M M Le Beau; M O Diaz; D Patterson; J D Rowley; H A Drabkin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Transient leukemia in down syndrome: report of two cases with review of literature.

Authors:  Alka V Gosavi; Prashant S Murarkar; Dhaneshwar N Lanjewar; Ravishankar V Ravikar
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-21       Impact factor: 0.900

3.  Down syndrome with transient myeloproliferative disorder and Beta-thalassemia major.

Authors:  Amit Garg; Ankur Singh; Mohanaraj Ramachandran; Seema Kapoor
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-22       Impact factor: 0.900

4.  Leukaemia and transient leukaemia in Down syndrome.

Authors:  L Iselius; P Jacobs; N Morton
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.